deltatrials
Completed PHASE1 NCT00016874

3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer

A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer

Sponsor: Vion Pharmaceuticals

Conditions Unspecified Adult Solid Tumor, Protocol Specific
Interventions cisplatin paclitaxel triapine
Updated 6 times since 2017 Last updated: Jul 17, 2013 Started: Dec 31, 2000 Completion: Jan 31, 2008

Listed as NCT00016874, this PHASE1 trial focuses on Unspecified Adult Solid Tumor, Protocol Specific and remains completed. Sponsored by Vion Pharmaceuticals, it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Dec 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vion Pharmaceuticals
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States
  • • The Bronx, United States